To further explore the mechanisms underlying the suppressive effect of pharmacological VC on mTORC1 activation, we examined whether pharmacological VC inhibits mTOR through AMPK or MAPK, reported to be the mechanism mediating the tumor-killing properties of pharmacological VC [16, 17]. Here, MTOR is linked to neoplasm.